Should Big Pharma Redirect Resources From Early R&D?
Executive Summary
With pharma under pressure from patent expirations and lack of innovative new products, research productivity is a hot button issue. Large drug companies increasingly rely on external sources to fill pipelines, but some industry observers say they're not going far enough.
You may also be interested in...
Sanofi Makes Good On Outsourcing Promise In Deal With Covance
Sanofi-Aventis, which last year announced plans to transform its R&D model by tapping external sources, announced a multi-layered 10-year partnership with the contract research organization Covance Sept. 30.
Lilly Tries to Buy Time
Facing a steep patent cliff and a dearth of late-stage drugs, Lilly is slashing expenses, reorganizing R&D, and hoping to attract investors to share the risks and rewards of pipeline development. Will these moves be enough?
Covance R&D Deal Meshes With Lilly’s “FIPNet” Model
Lilly has deepened its commitment to its fully integrated pharmaceutical network strategy, most recently adding a deal with the contract research organization Covance